VHL GENE INACTIVATION

Clinical trials for VHL GENE INACTIVATION explained in plain language.

Never miss a new study

Get alerted when new VHL GENE INACTIVATION trials appear

Sign up with your email to follow new studies for VHL GENE INACTIVATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New pill shows promise for rare kidney cancer in VHL patients

Disease control Ongoing

This phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.

Matched conditions: VHL GENE INACTIVATION

Phase: PHASE2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control

Last updated Jun 22, 2026 11:59 UTC

VHL GENE INACTIVATION

Get alerted when new VHL GENE INACTIVATION trials appear

New pill shows promise for rare kidney cancer in VHL patients